Literature DB >> 24323986

Incidence and biological significance of IKZF1/Ikaros gene deletions in pediatric Philadelphia chromosome negative and Philadelphia chromosome positive B-cell precursor acute lymphoblastic leukemia.

Sanjive Qazi1, Fatih M Uckun.   

Abstract

Entities:  

Keywords:  IKZF1 deletions; copy number abnormalities; pediatric Ph- BCP-ALL; prognosis

Mesh：

Substances：

Year:  2013        PMID： 24323986      PMCID： PMC3856976          DOI： 10.3324/haematol.2013.091140

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  11 in total

1.  IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol.

Authors:  Petra Dörge; Barbara Meissner; Martin Zimmermann; Anja Möricke; André Schrauder; Jean-Pierre Bouquin; Denis Schewe; Jochen Harbott; Andrea Teigler-Schlegel; Richard Ratei; Wolf-Dieter Ludwig; Rolf Koehler; Claus R Bartram; Martin Schrappe; Martin Stanulla; Gunnar Cario
Journal:  Haematologica       Date:  2012-08-08       Impact factor: 9.941

2.  Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study.

Authors:  I-Ming Chen; Richard C Harvey; Charles G Mullighan; Julie Gastier-Foster; Walker Wharton; Huining Kang; Michael J Borowitz; Bruce M Camitta; Andrew J Carroll; Meenakshi Devidas; D Jeanette Pullen; Debbie Payne-Turner; Sarah K Tasian; Shalini Reshmi; Catherine E Cottrell; Gregory H Reaman; W Paul Bowman; William L Carroll; Mignon L Loh; Naomi J Winick; Stephen P Hunger; Cheryl L Willman
Journal:  Blood       Date:  2012-02-24       Impact factor: 22.113

3.  Ikaros (IKZF1) alterations and minimal residual disease at day 15 assessed by flow cytometry predict prognosis of childhood BCR/ABL-negative acute lymphoblastic leukemia.

Authors:  Jana Volejnikova; Ester Mejstrikova; Petra Dörge; Barbara Meissner; Olga Zimmermannova; Karel Svojgr; Martin Stanulla; Gunnar Cario; Martin Schrappe; Jan Stary; Ondrej Hrusak; Jan Trka; Eva Fronkova
Journal:  Pediatr Blood Cancer       Date:  2012-09-19       Impact factor: 3.167

Review 4.  Antigen receptor allelic exclusion: an update and reappraisal.

Authors:  Brenna L Brady; Natalie C Steinel; Craig H Bassing
Journal:  J Immunol       Date:  2010-10-01       Impact factor: 5.422

5.  Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group.

Authors:  Torsten Haferlach; Alexander Kohlmann; Lothar Wieczorek; Giuseppe Basso; Geertruy Te Kronnie; Marie-Christine Béné; John De Vos; Jesus M Hernández; Wolf-Karsten Hofmann; Ken I Mills; Amanda Gilkes; Sabina Chiaretti; Sheila A Shurtleff; Thomas J Kipps; Laura Z Rassenti; Allen E Yeoh; Peter R Papenhausen; Wei-Min Liu; P Mickey Williams; Robin Foà
Journal:  J Clin Oncol       Date:  2010-04-20       Impact factor: 44.544

6.  What is the relevance of Ikaros gene deletions as a prognostic marker in pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia?

Authors:  Chiara Palmi; Maria Grazia Valsecchi; Giulia Longinotti; Daniela Silvestri; Valentina Carrino; Valentino Conter; Giuseppe Basso; Andrea Biondi; Geertruy Te Kronnie; Giovanni Cazzaniga
Journal:  Haematologica       Date:  2013-04-12       Impact factor: 9.941

7.  Serine phosphorylation by SYK is critical for nuclear localization and transcription factor function of Ikaros.

Authors:  Fatih M Uckun; Hong Ma; Jian Zhang; Zahide Ozer; Sinisa Dovat; Cheney Mao; Rita Ishkhanian; Patricia Goodman; Sanjive Qazi
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-15       Impact factor: 11.205

8.  Function of Ikaros as a tumor suppressor in B cell acute lymphoblastic leukemia.

Authors:  Philippe Kastner; Arnaud Dupuis; Marie-Pierre Gaub; Raoul Herbrecht; Patrick Lutz; Susan Chan
Journal:  Am J Blood Res       Date:  2013-01-17

9.  BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros.

Authors:  Charles G Mullighan; Christopher B Miller; Ina Radtke; Letha A Phillips; James Dalton; Jing Ma; Deborah White; Timothy P Hughes; Michelle M Le Beau; Ching-Hon Pui; Mary V Relling; Sheila A Shurtleff; James R Downing
Journal:  Nature       Date:  2008-04-13       Impact factor: 49.962

10.  Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia.

Authors:  Charles G Mullighan; Xiaoping Su; Jinghui Zhang; Ina Radtke; Letha A A Phillips; Christopher B Miller; Jing Ma; Wei Liu; Cheng Cheng; Brenda A Schulman; Richard C Harvey; I-Ming Chen; Robert J Clifford; William L Carroll; Gregory Reaman; W Paul Bowman; Meenakshi Devidas; Daniela S Gerhard; Wenjian Yang; Mary V Relling; Sheila A Shurtleff; Dario Campana; Michael J Borowitz; Ching-Hon Pui; Malcolm Smith; Stephen P Hunger; Cheryl L Willman; James R Downing
Journal:  N Engl J Med       Date:  2009-01-07       Impact factor: 91.245
View more
  3 in total

1.  Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622.

Authors:  William B Slayton; Kirk R Schultz; John A Kairalla; Meenakshi Devidas; Xinlei Mi; Michael A Pulsipher; Bill H Chang; Charles Mullighan; Ilaria Iacobucci; Lewis B Silverman; Michael J Borowitz; Andrew J Carroll; Nyla A Heerema; Julie M Gastier-Foster; Brent L Wood; Sherri L Mizrahy; Thomas Merchant; Valerie I Brown; Lance Sieger; Marilyn J Siegel; Elizabeth A Raetz; Naomi J Winick; Mignon L Loh; William L Carroll; Stephen P Hunger
Journal:  J Clin Oncol       Date:  2018-05-29       Impact factor: 44.544

2.  Absence of Genomic Ikaros/IKZF1 Deletions in Pediatric B-Precursor Acute Lymphoblastic Leukemia.

Authors:  Sanjive Qazi; Hong Ma; Fatih M Uckun
Journal:  Int J Mol Med Sci       Date:  2013-07-29

3.  Constitutive function of the Ikaros transcription factor in primary leukemia cells from pediatric newly diagnosed high-risk and relapsed B-precursor ALL patients.

Authors:  Fatih M Uckun; Hong Ma; Rita Ishkhanian; Martha Arellano; Anoush Shahidzadeh; Amanda Termuhlen; Paul S Gaynon; Sanjive Qazi
Journal:  PLoS One       Date:  2013-11-20       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.